#EASL 2016

Click Here for More Conferences

Click Here for EASL.eu

An Introduction to Hepatitis

Click Here for More Conferences

Click Here for EASL.eu

An Introduction to Hepatitis

Conferences

Coffee Could Protect Against Non-Alcoholic Fatty Liver Disease

Consuming coffee, even decaf, could protect against non-alcoholic fatty liver disease (NAFLD), according to a mouse study.

Success for 8 Weeks of Gilead’s All-Genotype Hepatitis C Regimen

Gilead’s experimental hepatitis C treatment for all genotypes boasted a high success rate among those treated for the first time.

Studies to Begin of $300 Generic Hepatitis C Treatment for International Use

Researchers are launching trials of a $300 generic hepatitis C regimen that could help expand treatment of the virus in poorer nations.

People Beat Hepatitis C Just As Well When Treated by Nonspecialists

People who receive hepatitis C treatment from community-based treatment providers are cured at the same rate as those who see specialists.

Without a Vaccine, Eliminating Hepatitis C Will Be a Huge Challenge

Jeffrey Lazarus interviews experts from the European Liver Patients Association about the changing field of viral hepatitis

MUST read

Hepatitis C: The Basics

Hepatitis B: The Basics

Hepatitis A: The Basics

Whether a Liver Transplant Has Hepatitis C Has No Bearing on Outcome for People With Hep C

People with hepatitis C do just as well with a liver transplant that is infected with the virus as those receiving an uninfected organ.

AbbVie’s Viekira Pak Works Just As Well in Those With Hepatitis C Drug Resistance

Having resistance to a particular class of hepatitis C drugs does not affect the likelihood of a cure with AbbVie’s Viekira Pak.

New Algorithm Predicts Who Will Benefit From End-Stage Liver Disease Treatment

Researchers have developed a new algorithm to predict who will benefit from intensive care unit treatment of end-stage liver disease.

Excellent Real-World Results for AbbVie’s Hepatitis C Regimen Viekira Pak

AbbVie’s hepatitis C virus (HCV) regimen Viekira Pak boasted excellent safety and efficacy data in a large, ongoing, real-world trial.

New Tenofovir Is As Good As, Safer Than Old Version for Hepatitis B

Gilead’s tenofovir alafenamide (TAF) combats hepatitis B comparably to and is safer than Viread (tenofovir disoproxil fumarate, or TDF).

#EASL 2016

Click Here for More Conferences

Click Here for EASL.eu

An Introduction to Hepatitis

Click Here for More Conferences

Click Here for EASL.eu

An Introduction to Hepatitis

Conferences

Coffee Could Protect Against Non-Alcoholic Fatty Liver Disease

Success for 8 Weeks of Gilead’s All-Genotype Hepatitis C Regimen

Studies to Begin of $300 Generic Hepatitis C Treatment for International Use

People Beat Hepatitis C Just As Well When Treated by Nonspecialists

Without a Vaccine, Eliminating Hepatitis C Will Be a Huge Challenge

MUST read

Hepatitis C: The Basics

Hepatitis B: The Basics

Hepatitis A: The Basics

Whether a Liver Transplant Has Hepatitis C Has No Bearing on Outcome for People With Hep C

AbbVie’s Viekira Pak Works Just As Well in Those With Hepatitis C Drug Resistance

New Algorithm Predicts Who Will Benefit From End-Stage Liver Disease Treatment

Excellent Real-World Results for AbbVie’s Hepatitis C Regimen Viekira Pak

New Tenofovir Is As Good As, Safer Than Old Version for Hepatitis B

Hot topics

Forums: Support and discussion

Blogs: The community speaks

Hepatitis: The International Liver Congress Nine Years Later

European HIV-Positive Gay Men Cured of Hepatitis C Are Reinfected at Very High Rate

Can You Get Away With an Even Shorter Hepatitis C Treatment?

Those Who Fail Hepatitis C Treatment Have an Excellent Subsequent Shot

The Latest Hepatitis C Data from EASL

Science News

Newsfeed

Features

Ask Hep